Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 189

Just a quick vid. He mentions the hope of replacing current gene therapy with a pill or three which I heard Cynthia Kenyon say many years ago.

Dr David Sinclair talks about longevity genes, genes therapies and his works on resetting the eyes in this short clip.

David Sinclair is a professor in the Department of Genetics and co-director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, where he and his colleagues study sirtuins—protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction—as well as chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.

Continue reading “That Our Body Has A MEMORY OF YOUTH Has Been Proved | Dr David Sinclair Interview Clips” | >

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Bristle Discount Link (Oral microbiome quantification):
ConquerAging15
https://www.bmq30trk.com/4FL3LK/GTSC3/

TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.

Quantify Discount Link (At-Home Blood Testing)

Continue reading “Breaths Per Minute While Asleep: What’s Optimal?” | >

The CRISPR system, which involves a Cas enzyme to cut DNA, is a powerful tool for gene editing. But the genetic scissors sometimes make changes at the wrong place, creating a major safety problem that could limit their therapeutic use.

Now, scientists at the University of Texas (UT) at Austin have refined the Cas9 protein used in the Nobel Prize-winning CRISPR-Cas9 tool. The new version, dubbed SuperFi-Cas9, was thousands of times less likely to perform off-target editing but just as efficient at on-target editing as the original version, the team said in a paper published in Nature.

“This really could be a game-changer in terms of a wider application of the CRISPR-Cas systems in gene editing,” Kenneth Johnson, Ph.D., the study’s co-senior author, said in a statement.

Read more | >

Over the last several decades, obesity has rapidly grown to affect more than 2 billion people, making it one of the biggest contributors to poor health globally. Many individuals still have trouble losing weight despite decades of study on diet and exercise regimens. Researchers from Baylor College of Medicine and affiliated institutions now believe they understand why, and they argue that the emphasis should be shifted from treating obesity to preventing it.

The research team reports in the journal Science Advances that early-life molecular processes of brain development are likely a major determinant of obesity risk. Previous large human studies have shown that the genes most strongly associated with obesity are expressed in the developing brain. This most recent study in mice focused on epigenetic development. Epigenetics is a molecular bookmarking system that regulates whether genes are utilized or not in certain cell types.

“Decades of research in humans and animal models have shown that environmental influences during critical periods of development have a major long-term impact on health and disease,” said corresponding author Dr. Robert Waterland, professor of pediatrics-nutrition and a member of the USDA Children’s Nutrition Research Center at Baylor. “Body weight regulation is very sensitive to such ‘developmental programming,’ but exactly how this works remains unknown.”

Read more | >

Strange libraries of supplementary genes nicknamed “Borg” DNA appear to supercharge the microbes that possess them, giving them an uncanny ability to metabolize materials in their environment faster than their competitors.

By learning more about the way organisms use these unusual extrachromosomal packets of information, researchers are hoping to find new ways of engineering life to take a big bite out of methane emissions.

In the wake of a study publicized last year (and now published in Nature), researchers have continued to analyze the diversity of sequences methane-munching microbes store in these unusual genetic depositaries in an effort to learn more about the evolution of life.

Read more | >

(http://www.pharma.unizg.hr/en/about-us/staff/gordan–lauc, 450.html) is Professor of Biochemistry and Molecular Biology at the University of Zagreb, Faculty of Pharmacy and Biochemistry, and Founder and CEO of Genos Ltd. (https://genos-glyco.com/), a research-intensive SME located in Zagreb, Croatia with core of expertise in molecular genetics and glycomics (The comprehensive study the entire complement of sugars, whether free or present in more complex molecules of an organism) and they perform contract research, contract analysis and service for numerous universities, hospitals and private individuals in Europe and overseas.

Prof. Dr. Lauc also is CSO of GlycanAge LTD (https://glycanage.com/), a company that has developed a ground-breaking test that analyses your personal glycobiome for insights in improving your health and monitoring your biological age, and Co-Director of the Human Glycome Project (https://human-glycome.org/).

Prof. Dr. Lauc graduated with a degree in molecular biology at the University of Zagreb Faculty of Science in 1992, and obtained Ph.D. in Biochemistry and the University of Zagreb in 1995. He got his postdoctoral training at the Institute for Medical Physics and Biophysics in Münster and Johns Hopkins University in Baltimore. Since 1993 he has been employed at the Faculty of Pharmacy and Biochemistry in Zagreb. Between 1998 and 2010 he was also part-time employed at the University of Osijek School of Medicine where he founded a DNA laboratory for the identification of war victims and also served as Vice-Dean for Science between 2001 and 2005.

Prof. Dr. Lauc is author of over 100 research papers published in international journals and six international patents. He was invited to lecture at numerous international conferences, elected for visiting professor at the Johns Hopkins University and in 2011 also inducted in the prestigious Johns Hopkins Society of Scholars. If 2012 he was appointed Honorary Professor at the University of Edinburgh and Adjunct Professor at the Edith Cowan University in Perth.

Continue reading “Prof. Dr. Gordan Lauc, Ph.D. — Founder & CEO, Genos; CSO, GlycanAge; Advancing The Glycosciences” | >

Occupation-related stress and work characteristics are possible determinants of social inequalities in epigenetic aging but have been little investigated. Here, we investigate the association of several work characteristics with epigenetic age acceleration (AA) biomarkers.

The study population included employed and unemployed men and women (n = 631) from the UK Understanding Society study. We evaluated the association of employment and work characteristics related to job type, job stability; job schedule; autonomy and influence at work; occupational physical activity; and feelings regarding the job with four epigenetic age acceleration biomarkers (Hannum, Horvath, PhenoAge, GrimAge) and pace of aging (DunedinPoAm, DunedinPACE).

We fitted linear regression models, unadjusted and adjusted for established risk factors, and found the following associations for unemployment (years of acceleration): HorvathAA (1.51, 95% CI 0.08, 2.95), GrimAgeAA (1.53, 95% CI 0.16, 2.90) and 3.21 years for PhenoAA (95% CI 0.89, 5.33). Job insecurity increased PhenoAA (1.83, 95% CI 0.003, 3.67), while working at night was associated with an increase of 2.12 years in GrimAgeAA (95% CI 0.69, 3.55). We found effects of unemployment to be stronger in men and effects of night shift work to be stronger in women.

Read more | >